$BRKR
BRUKER CORP

2024 Q2 Form 10-Q Financial Statement

#000095017024057736 Filed on May 10, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $800.7M $721.7M $685.3M
YoY Change 17.42% 5.31% 15.18%
Cost Of Revenue $416.1M $368.9M $325.6M
YoY Change 21.88% 13.3% 12.78%
Gross Profit $384.6M $352.8M $359.7M
YoY Change 12.95% -1.92% 17.43%
Gross Profit Margin 48.03% 48.88% 52.49%
Selling, General & Admin $221.3M $195.3M $162.7M
YoY Change 24.4% 20.04% 11.67%
% of Gross Profit 57.54% 55.36% 45.23%
Research & Development $92.20M $81.80M $69.00M
YoY Change 29.86% 18.55% 21.91%
% of Gross Profit 23.97% 23.19% 19.18%
Depreciation & Amortization $45.20M $34.70M $25.10M
YoY Change 74.52% 38.25% 15.67%
% of Gross Profit 11.75% 9.84% 6.98%
Operating Expenses $336.5M $288.0M $237.0M
YoY Change 32.32% 21.52% 12.96%
Operating Profit $48.10M $64.80M $122.7M
YoY Change -44.2% -47.19% 27.15%
Interest Expense -$24.20M $5.000M $4.200M
YoY Change 178.16% 19.05% -268.0%
% of Operating Profit -50.31% 7.72% 3.42%
Other Income/Expense, Net -$24.20M $6.800M -$16.10M
YoY Change 178.16% -142.24% 544.0%
Pretax Income $23.90M $71.60M $106.6M
YoY Change -69.16% -32.83% 13.4%
Income Tax $16.10M $19.80M $29.90M
% Of Pretax Income 67.36% 27.65% 28.05%
Net Earnings $7.600M $50.90M $76.50M
YoY Change -86.69% -33.46% 24.19%
Net Earnings / Revenue 0.95% 7.05% 11.16%
Basic Earnings Per Share $0.05 $0.35 $0.52
Diluted Earnings Per Share $0.05 $0.35 $0.52
COMMON SHARES
Basic Shares Outstanding 145.3M 137.7M 146.7M
Diluted Shares Outstanding 148.0 145.9 147.6

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $169.7M $340.1M $597.9M
YoY Change -70.48% -43.12% -34.73%
Cash & Equivalents $169.7M $340.1M $597.9M
Short-Term Investments
Other Short-Term Assets $300.2M $264.4M $204.6M
YoY Change 23.49% 29.23% 13.04%
Inventory $1.176B $1.061B $858.8M
Prepaid Expenses $41.60M $33.50M
Receivables $507.2M $475.4M $471.7M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.153B $2.140B $2.133B
YoY Change -1.39% 0.35% -5.23%
LONG-TERM ASSETS
Property, Plant & Equipment $656.6M $586.1M $510.9M
YoY Change 25.62% 14.72% 26.52%
Goodwill $1.444B $751.9M $527.3M
YoY Change 158.79% 42.59% 37.21%
Intangibles $1.024B $449.2M $298.5M
YoY Change 240.98% 50.49% 31.21%
Long-Term Investments
YoY Change
Other Assets $185.5M $193.6M $294.2M
YoY Change -36.62% -34.19% 3.48%
Total Long-Term Assets $3.750B $2.366B $1.631B
YoY Change 124.03% 45.07% 25.46%
TOTAL ASSETS
Total Short-Term Assets $2.153B $2.140B $2.133B
Total Long-Term Assets $3.750B $2.366B $1.631B
Total Assets $5.903B $4.506B $3.764B
YoY Change 53.04% 19.73% 6.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $220.3M $199.1M $196.2M
YoY Change 16.68% 1.48% 21.71%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $26.40M $21.20M $120.1M
YoY Change -78.16% -82.35% 991.82%
Total Short-Term Liabilities $1.305B $1.183B $1.049B
YoY Change 24.13% 12.78% 19.08%
LONG-TERM LIABILITIES
Long-Term Debt $2.132B $1.357B $1.109B
YoY Change 89.93% 22.39% -8.0%
Other Long-Term Liabilities $641.6M $166.7M $395.6M
YoY Change 52.4% -57.86% -7.29%
Total Long-Term Liabilities $2.774B $1.524B $1.505B
YoY Change 79.7% 1.29% -7.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.305B $1.183B $1.049B
Total Long-Term Liabilities $2.774B $1.524B $1.505B
Total Liabilities $4.096B $3.056B $2.553B
YoY Change 57.14% 19.68% 1.61%
SHAREHOLDERS EQUITY
Retained Earnings $2.367B $2.367B
YoY Change
Common Stock $701.3M $291.1M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.237B $1.237B $1.107B
YoY Change 11.74% 11.74% 19.58%
Treasury Stock Shares $28.68M
Shareholders Equity $1.807B $1.415B $1.180B
YoY Change
Total Liabilities & Shareholders Equity $5.903B $4.506B $3.764B
YoY Change 53.04% 19.73% 6.0%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income $7.600M $50.90M $76.50M
YoY Change -86.69% -33.46% 24.19%
Depreciation, Depletion And Amortization $45.20M $34.70M $25.10M
YoY Change 74.52% 38.25% 15.67%
Cash From Operating Activities $900.0K $21.80M $87.50M
YoY Change -93.08% -75.09% 12.47%
INVESTING ACTIVITIES
Capital Expenditures $26.00M $21.40M $25.00M
YoY Change 10.64% -14.4% 31.58%
Acquisitions $274.5M $88.10M
YoY Change 211.58% 5.13%
Other Investing Activities -$1.299B -$282.8M -$83.20M
YoY Change 51876.0% 239.9% 0.48%
Cash From Investing Activities -$1.325B -$304.2M -$108.2M
YoY Change 4997.69% 181.15% 6.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $3.400M $2.100M
YoY Change 61.9%
Cash From Financing Activities 1.157B 151.7M -30.70M
YoY Change -11328.16% -594.14% -85.88%
NET CHANGE
Cash From Operating Activities 900.0K 21.80M 87.50M
Cash From Investing Activities -1.325B -304.2M -108.2M
Cash From Financing Activities 1.157B 151.7M -30.70M
Net Change In Cash -168.0M -148.3M -47.30M
YoY Change 621.03% 213.53% -81.24%
FREE CASH FLOW
Cash From Operating Activities $900.0K $21.80M $87.50M
Capital Expenditures $26.00M $21.40M $25.00M
Free Cash Flow -$25.10M $400.0K $62.50M
YoY Change 139.05% -99.36% 6.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001109354
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
000-30833
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
BRUKER CORPORATION
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3110160
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
40 Manning Road
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Billerica
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01821
CY2024Q1 dei City Area Code
CityAreaCode
978
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
663-3660
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2024Q1 dei Trading Symbol
TradingSymbol
BRKR
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
145335376
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
340100000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
488300000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
475400000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
492000000
CY2024Q1 us-gaap Inventory Net
InventoryNet
1060500000
CY2023Q4 us-gaap Inventory Net
InventoryNet
968300000
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
264400000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
215600000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
2140400000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
2164200000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
586100000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
599700000
CY2024Q1 us-gaap Goodwill
Goodwill
751900000
CY2023Q4 us-gaap Goodwill
Goodwill
582600000
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
449200000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
330500000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
105100000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
91700000
CY2024Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
280100000
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
297200000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
193600000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
184000000
CY2024Q1 us-gaap Assets
Assets
4506400000
CY2023Q4 us-gaap Assets
Assets
4249900000
CY2024Q1 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
21200000
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
121200000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
199100000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
202700000
CY2024Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
485200000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
400000000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
477000000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
478200000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1182500000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1202100000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1357300000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1160300000
CY2024Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
105600000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
91500000
CY2024Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
81800000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
67700000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
85700000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
74800000
CY2024Q1 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
76000000
CY2023Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
76600000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
166700000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
163600000
CY2024Q1 us-gaap Liabilities
Liabilities
3055600000
CY2023Q4 us-gaap Liabilities
Liabilities
2836600000
CY2024Q1 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
17900000
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
18700000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
260000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
260000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
176113521
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
175943705
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
145334642
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
145164826
CY2024Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1700000
CY2023Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1700000
CY2024Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
30778879
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
30778879
CY2024Q1 us-gaap Treasury Stock Value
TreasuryStockValue
1237200000
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
1237200000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
291100000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
282900000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2367400000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2323800000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7700000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6000000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
1415300000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1377200000
CY2024Q1 us-gaap Minority Interest
MinorityInterest
17600000
CY2023Q4 us-gaap Minority Interest
MinorityInterest
17400000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1432900000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1394600000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4506400000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4249900000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
721700000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
685300000
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
368900000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
325600000
CY2024Q1 us-gaap Gross Profit
GrossProfit
352800000
CY2023Q1 us-gaap Gross Profit
GrossProfit
359700000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
195300000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
162700000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
81800000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69000000
CY2024Q1 us-gaap Other Nonrecurring Expense
OtherNonrecurringExpense
10900000
CY2023Q1 us-gaap Other Nonrecurring Expense
OtherNonrecurringExpense
5300000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
288000000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
237000000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
64800000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
122700000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6800000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16100000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
71600000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
106600000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
19800000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29900000
CY2024Q1 brkr Equity In Income Of Unconsolidated Investees Net Of Tax
EquityInIncomeOfUnconsolidatedInvesteesNetOfTax
200000
CY2023Q1 brkr Equity In Income Of Unconsolidated Investees Net Of Tax
EquityInIncomeOfUnconsolidatedInvesteesNetOfTax
700000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
52000000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
77400000
CY2024Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1100000
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
900000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
50900000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
76500000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.35
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.52
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.35
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.52
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
145.2
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146.8
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
145.9
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147.6
CY2024Q1 us-gaap Profit Loss
ProfitLoss
52000000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
77400000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
2200000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-1400000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-77200000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
25800000
CY2024Q1 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsTax
-19100000
CY2023Q1 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsTax
3400000
CY2024Q1 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent
62100000
CY2023Q1 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent
-10700000
CY2024Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
100000
CY2023Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
500000
CY2024Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-600000
CY2023Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-100000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-14500000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
15200000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
37500000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
92600000
CY2024Q1 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
1100000
CY2023Q1 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
1300000
CY2024Q1 brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-800000
CY2023Q1 brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
0
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
37200000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
91300000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1394600000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3400000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4600000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
200000
CY2024Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2024Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7300000
CY2024Q1 brkr Loans To Noncontrolling Interest
LoansToNoncontrollingInterest
900000
CY2024Q1 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
52300000
CY2024Q1 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
-13700000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1432900000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1125700000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
700000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-100000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4100000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
200000
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
22300000
CY2023Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2023Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7400000
CY2023Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
5300000
CY2023Q1 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
77500000
CY2023Q1 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
15100000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1198800000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
52000000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
77400000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
34700000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25100000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5300000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6500000
CY2024Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2100000
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1200000
CY2024Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
1400000
CY2023Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
6900000
CY2024Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
9800000
CY2024Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
6100000
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-5000000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-15600000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8300000
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
64800000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
55000000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3700000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
13100000
CY2024Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-11900000
CY2023Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-5800000
CY2024Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
31700000
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
34800000
CY2024Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
30300000
CY2023Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
20200000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
21800000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
87500000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21400000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000000
CY2024Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
10000000
CY2023Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
8200000
CY2024Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
274500000
CY2023Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
88100000
CY2024Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
500000
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
10700000
CY2024Q1 us-gaap Payments For Proceeds From Hedge Investing Activities
PaymentsForProceedsFromHedgeInvestingActivities
-1200000
CY2023Q1 us-gaap Payments For Proceeds From Hedge Investing Activities
PaymentsForProceedsFromHedgeInvestingActivities
-2400000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-304200000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-108200000
CY2024Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
500000
CY2023Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0
CY2024Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
268900000
CY2023Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0
CY2024Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3400000
CY2023Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2100000
CY2024Q1 brkr Repayment Of Two Thousand Twelve Notes Purchase Agreement
RepaymentOfTwoThousandTwelveNotesPurchaseAgreement
-100000000
CY2023Q1 brkr Repayment Of Two Thousand Twelve Notes Purchase Agreement
RepaymentOfTwoThousandTwelveNotesPurchaseAgreement
0
CY2024Q1 brkr Repayment Of Two Thousand Nineteen Notes Purchase Agreement
RepaymentOfTwoThousandNineteenNotesPurchaseAgreement
-3800000
CY2023Q1 brkr Repayment Of Two Thousand Nineteen Notes Purchase Agreement
RepaymentOfTwoThousandNineteenNotesPurchaseAgreement
-3800000
CY2024Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
4700000
CY2023Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3400000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
700000
CY2024Q1 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
0
CY2023Q1 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
1000000
CY2024Q1 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
7300000
CY2023Q1 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
7400000
CY2024Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
22400000
CY2024Q1 us-gaap Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
-900000
CY2023Q1 us-gaap Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
5300000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
151700000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-30700000
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-17600000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4100000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-148300000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-47300000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
491600000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
648700000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
343300000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
601400000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3300000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3200000
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3200000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3500000
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<div style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Description of Business</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Bruker Corporation, together with its consolidated subsidiaries (Bruker or the Company), develops, manufactures and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. Many of the Company’s products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. The Company’s products address the rapidly evolving needs of a diverse array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology, in-vitro diagnostics, nanotechnology and materials science research.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">four</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segments, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID (Chemicals, Applied Markets, Life Science, In Vitro Diagnostics, Detection), BSI NANO and Bruker Energy &amp; Supercon Technologies (BEST).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BSI BioSpin Segment designs, manufactures and distributes enabling life science tools based on magnetic resonance technology. BSI BioSpin Segment’s revenues are generated by academic and government research customers, pharmaceutical and biotechnology companies and nonprofit laboratories, as well as chemical, food and beverage, clinical and other industrial companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BSI CALID Segment designs, manufactures and distributes life science mass spectrometry, applied mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies and radiological/nuclear detectors for Chemical, Biological, Radiological, Nuclear and Explosive (CBRNE) detection. Customers of the BSI CALID Segment include academic institutions and medical schools; pharmaceutical, biotechnology and diagnostics companies; contract research organizations; nonprofit and for-profit forensics laboratories; agriculture, food and beverage safety laboratories; environmental and clinical microbiology laboratories; hospitals and government departments and agencies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BSI NANO Segment designs, manufactures and distributes advanced X-ray instruments; atomic force microscopy instrumentation; advanced fluorescence optical microscopy instruments; analytical tools for electron microscopes and X-ray metrology; defect-detection equipment for semiconductor process control; handheld, portable and mobile X-ray fluorescence spectrometry instruments; spark optical emission spectroscopy systems; chip cytometry products and services for targeted spatial proteomics, multi-omic services; optofluidic and proteomic barcoding platforms; and products and services for spatial genomics research. Customers of the BSI NANO Segment include academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies and other businesses involved in materials research and life science research analysis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BEST Segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and “big science” research. The segment focuses on metallic low temperature superconductors for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The unaudited condensed consolidated financial statements represent the consolidated accounts of the Company. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements as of March 31, 2024 and December 31, 2023, and for the three months ended March 31, 2024 and 2023, have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, the financial information presented herein does not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair statement have been included. The results for interim periods are not necessarily indicative of the results expected for any other interim period or the full year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At March 31, 2024, the Company’s significant accounting policies, which are detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, have not changed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company is subject to the same risks and uncertainties as disclosed in its Annual Report on Form 10-K filed with the SEC on February 29, 2024, however, as of January 1, 2024, the Company is subject to new risks related to its self-funded health insurance. Effective January 1, 2024, the Company is self-insured for health care claims for eligible participating U.S. employees subject to certain deductibles and limitations. The Company determines its liability for claims incurred but not reported for insurance liabilities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an actuarial basis. Since there are many estimates and assumptions involved in recording insurance liabilities, differences between actual future events and prior estimates and assumptions, could result in materially different amounts of expense and result in adjustments to these liabilities and materially different amounts of expense, which could harm our business and adversely affect our results of operations and financial condition.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the unaudited condensed consolidated financial statements requires the Company to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis the Company evaluates estimates, judgments and methodologies. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the global supply chain interruptions, higher energy costs and shortages, the global economy, including inflation and the threat of recession, and geopolitical instability will directly or indirectly impact future business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee cost related amounts, will depend on future developments that are highly uncertain, including as a result of new developments concerning global supply chain and various global conflicts. The Company has made estimates of the impact of these disruptions within the financial statements and there may be changes to those estimates in future periods. Actual results may differ from management’s estimates if these results differ from historical experience.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the unaudited condensed consolidated financial statements requires the Company to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis the Company evaluates estimates, judgments and methodologies. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the global supply chain interruptions, higher energy costs and shortages, the global economy, including inflation and the threat of recession, and geopolitical instability will directly or indirectly impact future business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee cost related amounts, will depend on future developments that are highly uncertain, including as a result of new developments concerning global supply chain and various global conflicts. The Company has made estimates of the impact of these disruptions within the financial statements and there may be changes to those estimates in future periods. Actual results may differ from management’s estimates if these results differ from historical experience.</span>
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
721700000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
685300000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
721700000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
685300000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
721700000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
685300000
CY2024Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
2306300000
CY2024Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
92500000
CY2023Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
85800000
CY2024Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
590800000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
491400000
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
130400000
CY2023Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
28800000
CY2024Q1 us-gaap Derivative Assets Current
DerivativeAssetsCurrent
11800000
CY2023Q4 us-gaap Derivative Assets Current
DerivativeAssetsCurrent
1600000
CY2024Q1 us-gaap Asset Reporting Currency Denominated Value
AssetReportingCurrencyDenominatedValue
12800000
CY2023Q4 us-gaap Asset Reporting Currency Denominated Value
AssetReportingCurrencyDenominatedValue
12000000
CY2024Q1 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
16700000
CY2024Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
393100000
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
371200000
CY2024Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
360600000
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
314900000
CY2024Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
204200000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
183900000
CY2024Q1 us-gaap Other Inventory Demo
OtherInventoryDemo
102600000
CY2023Q4 us-gaap Other Inventory Demo
OtherInventoryDemo
98300000
CY2024Q1 us-gaap Inventory Net
InventoryNet
1060500000
CY2023Q4 us-gaap Inventory Net
InventoryNet
968300000
CY2024Q1 us-gaap Other Inventory In Transit
OtherInventoryInTransit
57600000
CY2023Q4 us-gaap Other Inventory In Transit
OtherInventoryInTransit
48600000
CY2024Q1 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
90800000
CY2023Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
83900000
CY2024Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
70000000
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
45900000
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
33500000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
26700000
CY2024Q1 us-gaap Deposits Assets Current
DepositsAssetsCurrent
28800000
CY2023Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
16700000
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
264400000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
215600000
CY2024Q1 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
281600000
CY2024Q1 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
8200000
CY2024Q1 us-gaap Business Combination Consideration Transferred Liabilities Incurred
BusinessCombinationConsiderationTransferredLiabilitiesIncurred
13400000
CY2024Q1 brkr Business Combination Consideration Transferred Working Capital Adjustment
BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment
-1800000
CY2024Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
9000000
CY2024Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
63800000
CY2024Q1 brkr Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets
2500000
CY2024Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
2700000
CY2024Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
27100000
CY2024Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
143500000
CY2024Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
288600000
CY2024Q1 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
41900000
CY2024Q1 brkr Payments To Acquire Businesses Cash Acquired
PaymentsToAcquireBusinessesCashAcquired
39800000
CY2023Q1 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
26700000
CY2023Q1 brkr Payments To Acquire Businesses Cash Acquired
PaymentsToAcquireBusinessesCashAcquired
19800000
CY2023Q1 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
6900000
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2023Q4 us-gaap Goodwill
Goodwill
582600000
CY2024Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
183100000
CY2024Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-13800000
CY2023Q3 us-gaap Goodwill
Goodwill
751900000
CY2024Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
813800000
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
364600000
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
449200000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
686300000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
355800000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
330500000
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
16200000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10700000
CY2024Q1 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2023Q1 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2024Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
1300000
CY2023Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
1300000
CY2024Q1 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
1359100000
CY2023Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
1260600000
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
1378500000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
1281500000
CY2024Q1 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
21200000
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
121200000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1357300000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1160300000
CY2024Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
1050100000
CY2024Q1 us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
255000000
CY2024Q1 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
150400000
CY2024Q1 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
644700000
CY2024Q1 brkr Decrease In Net Interest Expense Due To Derivative Instruments
DecreaseInNetInterestExpenseDueToDerivativeInstruments
4200000
CY2023Q1 brkr Decrease In Net Interest Expense Due To Derivative Instruments
DecreaseInNetInterestExpenseDueToDerivativeInstruments
4300000
CY2024Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
230000000
CY2024Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
269000000
CY2024Q1 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
747400000
CY2023Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
883300000
CY2024Q1 us-gaap Derivative Notional Amount
DerivativeNotionalAmount
2736200000
CY2024Q1 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
-2400000
CY2023Q4 us-gaap Derivative Notional Amount
DerivativeNotionalAmount
1777900000
CY2023Q4 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
-89600000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
19800000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29900000
CY2024Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.277
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.28
CY2024Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
60200000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
58500000
CY2024Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
6900000
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
5800000
CY2024Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
1200000
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
500000
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.043
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
50900000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
76500000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
145.2
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146.8
CY2024Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0.7
CY2023Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0.8
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
145.9
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147.6
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.35
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.52
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.35
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.52
CY2022Q3 brkr Excise Tax On Stock Repurchases
ExciseTaxOnStockRepurchases
0.01
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4800000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4300000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4800000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4300000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3100000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2024Q1 brkr Information Technology And Data Processing Cost Net
InformationTechnologyAndDataProcessingCostNet
800000
CY2023Q1 brkr Information Technology And Data Processing Cost Net
InformationTechnologyAndDataProcessingCostNet
500000
CY2024Q1 brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
3500000
CY2023Q1 brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
300000
CY2024Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
4100000
CY2023Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2900000
CY2024Q1 brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
2500000
CY2023Q1 brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
1600000
CY2024Q1 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
10900000
CY2023Q1 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
5300000
CY2024Q1 us-gaap Restructuring Charges
RestructuringCharges
7200000
CY2023Q1 us-gaap Restructuring Charges
RestructuringCharges
500000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
13100000
CY2024Q1 us-gaap Restructuring Charges
RestructuringCharges
7200000
CY2024Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
9100000
CY2024Q1 us-gaap Restructuring Reserve Translation And Other Adjustment
RestructuringReserveTranslationAndOtherAdjustment
-2900000
CY2024Q1 us-gaap Restructuring Reserve
RestructuringReserve
8300000
CY2023 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
3200000
CY2024Q1 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
1200000
CY2024Q1 brkr Modification Of Operating Leases
ModificationOfOperatingLeases
0
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2600000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1400000
CY2024Q1 us-gaap Interest Expense
InterestExpense
5000000
CY2023Q1 us-gaap Interest Expense
InterestExpense
4200000
CY2024Q1 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
0
CY2023Q1 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
6900000
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
8900000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3300000
CY2024Q1 us-gaap Net Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component
NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
-300000
CY2023Q1 us-gaap Net Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component
NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
100000
CY2024Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0
CY2023Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-3000000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6800000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16100000
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
8900000
CY2024Q1 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
1800000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
64800000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
122700000
CY2024Q1 us-gaap Assets
Assets
4506400000
CY2023Q4 us-gaap Assets
Assets
4249900000
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-057736-index-headers.html Edgar Link pending
0000950170-24-057736-index.html Edgar Link pending
0000950170-24-057736.txt Edgar Link pending
0000950170-24-057736-xbrl.zip Edgar Link pending
brkr-20240331.htm Edgar Link pending
brkr-20240331.xsd Edgar Link pending
brkr-ex31_1.htm Edgar Link pending
brkr-ex31_2.htm Edgar Link pending
brkr-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
brkr-20240331_htm.xml Edgar Link completed
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable